Novavax Inc (NVAX)

Currency in USD
8.980
-0.290(-3.13%)
Closed·
8.994+0.014(+0.15%)
·
NVAX is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
8.9409.235
52 wk Range
6.13011.970
Key Statistics
Prev. Close
9.27
Open
9.154
Day's Range
8.94-9.235
52 wk Range
6.13-11.97
Volume
3.21M
Average Volume (3m)
4.72M
1-Year Change
26.301%
Book Value / Share
-0.89
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
NVAX Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
14.113
Upside
+57.16%
Members' Sentiments
Bearish
Bullish
ProTips
Analysts anticipate sales decline in the current year

Novavax Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Analyst Ratings

5 Buy
1 Hold
3 Sell
Ratings:
9 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 14.113
(+57.16% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
TD Cowen
Hold9.00+0.22%8.00MaintainMay 06, 2026
H.C. Wainwright
Buy16.00+78.17%-MaintainApr 21, 2026
B.Riley
Buy18.00+100.45%16.00MaintainApr 09, 2026
Jefferies
Buy25.00+178.40%-MaintainMar 12, 2026
H.C. Wainwright
Buy16.00+78.17%11.00MaintainFeb 27, 2026

Novavax Inc Earnings Call Summary for Q1/2026

  • Novavax Q1 2026 EPS of -$0.06 beat forecast of -$0.24 by 75%; revenue of $140M exceeded projections by 75.9%, driving 12.96% premarket stock surge
  • Net loss narrowed to $9M despite 79% YoY revenue decline; drop attributed to prior year's one-time non-cash NUVAXOVID revenue recognition event
  • Company transitions from COVID vaccine reliance to diversified partner-based model; Matrix-M adjuvant demand and licensing royalties fuel growth
  • Full-year 2026 revenue guidance set at $230M-$270M; cash position of $818M extends runway into 2028 with profitability expected this year
  • Strategic focus on Sanofi partnership and Matrix-M platform expansion; risks include market saturation, partner dependency, and regulatory challenges
Last Updated: 05/06/2026, 11:44 PM
Read Full Transcript

Earnings

Latest Release
May 06, 2026
EPS / Forecast
-0.06 / -0.24
Revenue / Forecast
139.51M / 79.31M
EPS Revisions
Last 90 days

NVAX Income Statement

Compare NVAX to Peers and Sector

Metrics to compare
NVAX
Peers
Sector
Relationship
P/E Ratio
−17.4x−3.2x−0.5x
PEG Ratio
0.150.020.00
Price/Book
−10.5x2.2x2.6x
Price / LTM Sales
2.6x7.1x3.1x
Upside (Analyst Target)
72.8%213.7%54.0%
Fair Value Upside
Unlock0.1%6.5%Unlock

Novavax, Inc., a biotechnology company, engages in the discovery, development, and commercialization of vaccines to prevent serious infectious diseases in the United States, Europe, and internationally. The company commercializes Nuvaxovid, a COVID-19 vaccine; and R21 Matrix-M adjuvant malaria vaccine. It has license and collaboration agreements with Sanofi, Pfizer Inc., Takeda Pharmaceutical Company Limited, and Serum Life Sciences Limited for the to develop, manufacture, and commercialize the COVID-19 vaccine. The company was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
40.52M24.64%360.63M
Other Institutional Investors
89.23M54.26%794.15M
Public Companies & Retail Investors
34.69M21.09%308.72M
Total
164.44M100.00%1.46B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
The Vanguard Group, Inc.9.41%15,470,365143,410
Shah Capital Management, Inc8.95%14,719,738136,452

People Also Watch

96.220
ASTS
+7.41%
99.66
NOW
-3.52%
1,542.64
SNDK
+10.78%
47.27
MRNA
-1.77%
44.39
NVO
-1.51%

FAQ

What Is the Novavax (NVAX) Stock Price Today?

The Novavax stock price today is 8.980 USD.

What Stock Exchange Does Novavax Trade On?

Novavax is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Novavax?

The stock symbol for Novavax is "NVAX."

What Is the Novavax Market Cap?

As of today, Novavax market cap is 1.480B USD.

What Is Novavax's Earnings Per Share (TTM)?

The Novavax EPS (TTM) is -0.540.

When Is the Next Novavax Earnings Date?

Novavax will release its next earnings report on Aug 12, 2026.

From a Technical Analysis Perspective, Is NVAX a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.

How Many Times Has Novavax Stock Split?

Novavax has split 1 times.

How Many Employees Does Novavax Have?

Novavax has 749 employees.

What is the current trading status of Novavax (NVAX)?

As of May 21, 2026, Novavax (NVAX) is trading at a price of 8.980 USD, with a previous close of 9.270 USD. The stock has fluctuated within a day range of 8.940 USD to 9.235 USD, while its 52-week range spans from 6.130 USD to 11.970 USD.

What Is Novavax (NVAX) Price Target According to Analysts?

The average 12-month price target for Novavax is 14.113 USD, with a high estimate of 25 USD and a low estimate of 7 USD. 5 analysts recommend buying the stock, while 3 suggest selling, leading to an overall rating of Buy. The stock has an +57.16% Upside potential.

What Is the NVAX Premarket Price?

NVAX's last pre-market stock price is 9.200 USD. The pre-market share volume is 38,710.000, and the stock has decreased by -0.070, or -0.760%.

What Is the NVAX After Hours Price?

NVAX's last after hours stock price is 8.994 USD, the stock has decreased by 0.014, or 0.150%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.